Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Abstract Introduction In the phase 3 TACKLE study, outpatient treatment with AZD7442 (tixagevimab/cilgavimab) was well tolerated and significantly reduced progression to severe disease or death through day 29 in adults with mild-to-moderate coronavirus disease 2019 (COVID-19) at the primary analysis...

Full description

Bibliographic Details
Main Authors: F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S. Cohen, Mark T. Esser
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Infectious Diseases and Therapy
Subjects:
Tixagevimab
Cilgavimab
COVID-19
Monoclonal antibody
Clinical trial
Online Access:https://doi.org/10.1007/s40121-024-00931-4

Internet

https://doi.org/10.1007/s40121-024-00931-4

Similar Items